Royal Care Super Specialty Hospital began its journey as a 50-bed multi-specialty hospital on May 1, 2015, in Coimbatore, Tamil Nadu. Within a year, the hospital gained significant recognition for its quality of care, becoming a preferred healthcare destination for many in western Tamil Nadu. The hospital's commitment to excellence necessitated expansion, leading to the establishment of a larger and more comprehensive tertiary care unit.
Recognizing the need for a state-of-the-art facility, Royal Care Super Specialty Hospital embarked on an ambitious expansion project. A 750-bed ultramodern facility was constructed at Neelambur, Coimbatore, within a record time of 400 days. The first phase, comprising 300 beds, was inaugurated in November 2016. Spanning over 300,000 square feet, the facility is equipped with the latest medical technologies and infrastructure to provide comprehensive healthcare services under one roof.
Royal Care Super Specialty Hospital has introduced several pioneering medical treatments and technologies in India. It became the first hospital in the country to offer Bronchial Thermoplasty, a cutting-edge treatment for severe asthma. Additionally, the hospital introduced microplasma advanced oxidation for dialysis feed water disinfection, effectively eliminating endotoxins and preventing pyrogenic reactions in hemodialysis patients.
At the heart of Royal Care's success is its unwavering commitment to patient-centered care. The hospital ensures that every patient receives warm and dedicated attention, fostering a culture of compassion and excellence. This patient-centric approach has been instrumental in the hospital's rapid growth and the enduring trust of its patients.
The hospital's growth is not just limited to infrastructure. By the end of its third year of operations, Royal Care had established a third center in Vellalore, Coimbatore, in collaboration with Coimbatore Round Table 20. This outreach center further extends the hospital's mission of providing high-quality healthcare to all sections of society.
Royal Care Super Specialty Hospital's success can be attributed to the visionary leadership of its Chairman. The Chairman's vision was to assemble a team of highly skilled medical professionals with exceptional expertise in their respective fields. This vision included integrating innovative diagnostic and therapeutic technologies and fostering a team of friendly medical and paramedical staff to deliver courteous and compassionate care with a personal touch.
Royal Care Super Specialty Hospital offers a wide range of medical services across various specialties. These include:
Royal Care Super Specialty Hospital is poised for continued growth and innovation in the healthcare sector. The hospital aims to maintain its position as a leading healthcare provider by continually adopting the latest medical advancements and expanding its services. The hospital's dedication to making modern healthcare accessible to all strata of society remains a core part of its mission.
Royal Care Super Specialty Hospital stands as a beacon of excellence in the healthcare sector, driven by a patient-centered approach, pioneering medical advancements, and visionary leadership. The hospital's journey from a 50-bed facility to a 750-bed ultramodern healthcare institution reflects its commitment to providing high-quality medical care and its role as a dependable destination for comprehensive healthcare.
P&L Statement | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Revenue | 221 | 301 | 305 | 333 |
Cost of Material Consumed | 70 | 97 | 98 | 106 |
Gross Margins | 68.33 | 67.77 | 67.87 | 68.17 |
Change in Inventory | 0 | 0 | 0 | -2 |
Employee Benefit Expenses | 36 | 53 | 54 | 54 |
Other Expenses | 60 | 83 | 92 | 108 |
EBITDA | 55 | 68 | 61 | 67 |
OPM | 24.89 | 22.59 | 20 | 20.12 |
Other Income | 3 | 4 | 5 | 5 |
Finance Cost | 29 | 27 | 27 | 22 |
D&A | 25 | 24 | 24 | 25 |
EBIT | 30 | 44 | 37 | 42 |
EBIT Margins | 13.57 | 14.62 | 12.13 | 12.61 |
PBT | 4 | 21 | 16 | 24 |
PBT Margins | 1.81 | 6.98 | 5.25 | 7.21 |
Tax | 0 | 0 | 0 | 0 |
PAT | 4 | 21 | 16 | 24 |
NPM | 1.81 | 6.98 | 5.25 | 7.21 |
EPS | 0.24 | 1.28 | 0.97 | 1.4 |
Financial Ratios | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Operating Profit Margin | 24.89 | 22.59 | 20 | 20.12 |
Net Profit Margin | 1.81 | 6.98 | 5.25 | 7.21 |
Earning Per Share (Diluted) | 0.24 | 1.28 | 0.97 | 1.4 |